Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Interest-Expense" stands at 0.667 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 06/30/2023.
Johnson & Johnson's third quarter result of 0.018 Billion USD for the item "Interest Expense" represents a decrease of -94.16 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 0.018 Billion USD for the item "Interest Expense" represents a decrease of -90.67 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 0.667 Billion USD for the item "Interest Expense" represents a decrease of -20.78 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -13.26 percent compared to the value the year prior.
The 1 year change in percent is -13.26.
The 3 year change in percent is 222.22.
The 5 year change in percent is 235.18.
The 10 year change in percent is 25.61.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Interest Expense | 905,699,262,464.00 |
![]() | AbbVie Inc - Interest Expense | 399,570,305,024.00 |
![]() | Roche Holding AG - Interest Expense | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Interest Expense | 280,205,508,085.11 |
![]() | Novartis AG - Interest Expense | 255,096,620,580.91 |